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ABSTRACT
Background and Objectives: Primary prevention of coronary artery disease (CAD) has become a public health issue, ac-
cording to increasing awareness of the substantial risks posed by asymptomatic atherosclerosis. The aims of this study were 
to determine the prevalence and characteristics of subclinical CAD using coronary computed tomography angiography 
(CCTA), and to evaluate the role of this advanced technology in identifying subclinical CAD in asymptomatic Korean indi-
viduals, compared with conventional risk stratification. Subjects and Methods: We enrolled 4,320 consecutive asymptom-
atic individuals (61% males, aged 50±9 years), who underwent 64-slice CCTA during a routine health check. Results: Coro-
nary artery plaques were present in 1,053 (24%) individuals. Significant stenosis (diameter stenosis ≥50%) was identified in 139 
(3%) subjects, and most of the significant lesions (87%) were located in the left anterior descending artery. CCTA revealed non-
calcified plaques in 5% of subjects with a coronary calcium score of zero (n=801). Although 25% (n=10) of those with noncal-
cified plaque had significant stenosis, most of them (90%) were classified into low- or moderate-risk groups according to Na-
tional Cholesterol Education Program risk stratification guidelines. In a young population (age ≤55 years for males, ≤65 years 
for females), 30% of subjects with significant stenosis were classified into a low-risk group and 60% had low (0 to 100) calcium 
scores. Conclusion: Subclinical CAD in asymptomatic individuals cannot be ignored for its considerable prevalence, CCTA 
may be helpful in identifying at-risk subclinical CAD in a noninvasive manner, especially in the young and traditionally low-
risk population. (Korean Circ J 2010;40:434-441)
KEY WORDS: Coronary artery disease; Primary prevention; Tomography scanners, X-ray computed.
Received: November 10, 2009
Accepted: March 30, 2010
Correspondence: Byunghee Oh, MD, Department of Internal Medi-
cine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-
gu, Seoul 110-744, Korea
Tel: 82-2-2072-2500, Fax: 82-2-2072-3757
E-mail: ohbhmed@snu.ac.kr
cc  This is an Open Access article distributed under the terms of the Cre-
ative Commons Attribution Non-Commercial License (http://creativecom-
mons.org/licenses/by-nc/3.0) which permits unrestricted non-commer-
cial use, distribution, and reproduction in any medium, provided the origi-
nal work is properly cited.
Introduction
Coronary artery disease (CAD) is the single most common 
cause of death in American men and women.1) After decades 
of declining CAD death rates, the incidence of acute coronary 
syndromes has continued to rise in the United States.2) More-
over, approximately 21% of first and recurrent annual myo-
cardial infarctions are silent.3) This has led to increased empha-
sis on primary prevention of atherosclerotic cardiovascular 
disease.
Identifying individuals at risk based on classical cardiovas-
cular risk factors is difficult, since 25 to 50% of patients expe-
riencing myocardial infarctions do not have any conventional 
Framingham risk factors.4) Specific algorithms such as those 
in the National Cholesterol Education Panel (NCEP) III gui-
delines have shown limited predictive power, especially in 
low-risk populations.5) Furthermore, these algorithms under-
estimate the risk of cardiovascular events, especially in young 
adults.6) For these reasons, a new screening modality for as-
sessing risk of cardiovascular events in an asymptomatic pop-
ulation is necessary.
Stress testing, including treadmill exercise stress tests or 
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single-photon emission computed tomography (SPECT) im-
aging, has been known to be inadequate for screening for 
subclinical CAD.7)8) Although coronary angiography (CAG) 
is generally used for diagnosing the presence of CAD9), it is 
undesirable for use as a screening tool in asymptomatic subjects 
because of its highly invasive nature. With the advent of elec-
tron-beam computed tomography (EBCT) in the 1990s, how-
ever, there have been attempts to develop coronary artery calci-
um score (CACS) guidelines for screening for subclinical 
CAD.10-15) Furthermore, coronary CT angiography (CCTA) can 
not only determine coronary artery calcium scores (CACSs), but 
also evaluate stenosis with the same resolution as conventional 
CAG.16) Therefore, CCTA can determine the characteristics and 
locations of plaques with reasonable accuracy, and its develop-
ment as a modality which can replace previous diagnostic me-
thods has been anticipated.17)18)
The purpose of this study was to determine the prevalence 
of CAD in an asymptomatic population using CCTA, and to 
discover how the conventional office-based risk stratifica-
tion methods such as the National Cholesterol Education Pro-
gram (NCEP) guidelines, and CACSs affect this population.
Subjects and Methods
Study population
From December 2005 until February 2008, we consecu-
tively enrolled 5,024 self-referred individuals who had un-
dergone CCTA evaluations using 64-slice cardiac multidetec-
tor computed tomography (MDCT) during routine general 
health checks at Seoul National University Bundang Hospital 
(SNUBH). Excluded from the study analysis were 704 individ-
uals who had chest pain or discomfort prior to enrollment, a 
history of myocardial infarction or angina, incomplete medi-
cal records, or were aged under 35 or over 75 years (Fig. 1). 
Final enrollment consisted of, 4,320 asymptomatic middle-
aged individuals (2,615 men and 1,705 women; aged 50±9 
years) free of known cardiovascular diseases. All subjects pro-
vided written, informed consent, and the institutional review 
board approved the study protocol.
Risk stratification
Basic demographic and clinical data were acquired from a 
database maintained by the SNUBH Health Promotion Cen-
ter. Framingham risk scores were calculated base on the NCEP 
guidelines.19) According to the revised NCEP guidelines, all sub-
jects were assigned to three different risk groups: high-risk 
{coronary heart disease (CHD), CHD risk equivalents, or 10-
year risk >20%}, moderate-risk (more than 2 risk factors and 
10-year risk ≤20%) and low-risk group (0 to 1 risk factor).
Data acquisition
Patients with a heart rate >70 beats per minute received in-
travenous esmolol, 10-30 mg (Jeil Pharm. Co., Ltd., Korea) be-
fore MDCT imaging. CCTA was performed using a 64-slice 
MDCT scanner (Brilliance 64; Philips Medical Systems, Best, 
The Netherlands). A standard scanning protocol was applied, 
with 64×0.625 mm section collimation, 420 msec/rotation 
gantry speed, 120 kV tube voltage, 800 mA tube current. A bo-
lus of 80 mL iomeprol (Iomeron 400; Bracco, Milan, Italy) 
was intravenously injected (4 mL/sec) followed by a 50 mL sa-
line chaser.
A region of interest was placed within the lumen of the 
descending thoracic aorta, and image acquisition was auto-
matically initiated once a selected threshold {150 Hounsfield 
units (HU)} had been reached using bolus tracking. The pa-
tient’s electrocardiogram was simultaneously recorded to al-
low for retrospective segmental data reconstruction. Images 
were initially reconstructed at the mid-diastolic phase (80% 
of R-R interval) of the cardiac cycle. Additional reconstruc-
tions were performed if motion artifacts were present. The 
mean radiation exposure of CTA was 13.2±0.8 mSv (13.2± 
0.8 for males and 13.3±0.8 for females).
Image analysis
All scans were independently analyzed using 3-dimen-
sional workstation (Brilliance; Philips Medical Systems, Best, 
The Netherlands), by each of two experienced investigators, 
who were blinded to the clinical information. After the inde-
pendent evaluations, a consensus interpretation was made 
to obtain the final MDCT diagnosis. Each lesion was identi-
fied using a multiplanar reconstruction (MPR) technique 
and maximum intensity projection (MIP) of the short-axis, 
2-chamber, and 4-chamber views. 
The contrast-enhanced portion of the coronary lumen was 
semiautomatically traced at the site of maximum stenosis. 
The luminal diameters of the maximal stenotic site were 
Fig. 1. Study protocol. CCTA: coronary CT angiography, AMI: acute 
myocardial infarction.
24,281 people screened
5,024 undergone CCTA
4,320 enrolled
19,257 did not undergo
CCTA evaluation
704 excluded
Age <35 or Age >75
Chest pain or discomfort
History of Angina/AMI
Insufficient medical records
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compared with the mean value of proximal and distal refer-
ence sites. If the image was inadequate or of poor quality, coro-
nary segments were visually scored to grade coronary artery 
stenosis. The severity of diameter stenosis was graded as nor-
mal (0 to 24%), mild (25 to 49%), moderate (50 to 74%), and 
severe (≥75%) narrowing. A diameter stenosis more than 
50% was defined as significant.
Coronary artery calcium score category definition
We divided the coronary artery into 15 segments and ana-
lyzed plaque characteristics, degree of coronary stenosis, and 
CACS from each segment. On the basis of the CACS, all pla-
ques were categorized as follows: no, 0; mild, 0.1 to 100; mo-
derate, 100.1 to 400; and severe calcification, >400.
Statistical analysis
Continuous variables are expressed as means±standard 
deviation (SD), whereas categorical variables are presented as 
absolute values and percentages. Differences between contin-
uous variables were analyzed by the unpaired Student t-test, 
and those between categorical variables by the chi-square test 
or the Fisher exact test, as appropriate. A p of <0.05 was consid-
ered statistically significant. All statistical analyses were perform-
ed using Statistical Package for the Social Sciences, version 
16.0. 
Results
Clinical characteristics of study population
Clinical characteristics of the study population are describ-
ed in Table 1. 
Most of the study population (n=3,935, 91%) were classi-
fied into the low- (n=2,645, 61%) or moderate- (n= 1,290, 
30%) risk groups according to NCEP guidelines; whereas the 
high-risk group comprised 9% of the study population 
(n=385). Most female subjects (n=1,384, 81%) were in the 
low-risk group, whereas half (n=1,261, 48%) the male subjects 
were classified into that group. 
Table 1. Clinical characteristics of an asymptomatic study population
Total (n=4,320) Male (n=2,615) Female (n=1,705)
Age (years ) 50±9 49±9* 50±9
BMI (kg/m2) 24.0±2.9 24.6±2.7* 23.0±3.0
Obesity (BMI >25) 1,533 (35) 1,153 (44)* 380 (22)
Hypertension 0.825 (19) 0.556 (21)* 269 (16)
Diabetes .341 (8) 0.262 (10)* 79 (5)
Dyslipidemia .322 (7) .227 (9)* 95 (6)
Smoking 1,137 (26) 1,075 (41)* 62 (4)
Family Hx of premature CAD 0.525 (12) .302 (12) 223 (13)
FRS (10 year-risk) 05.1±5.4 7.7±5.5* 01.3±1.8
NCEP-ATP III risk stratification
High risk group .385 (9) 0.301 (12)* 84 (5)
Moderate risk group 1,290 (30) 1,053 (40)* 237 (14)
Low risk group 2,645 (61) 1,261 (48)* 1,384 (81)0.
CACS 0021.1±127.5 0029.6±158.7* 008.2±47.8
Systolic blood pressure (mmHg) 117.5±15.1 119.2±14.1* 114.7±16.1
Diastolic blood pressure (mmHg) 072.6±11.4 075.6±10.7* 068.0±11.0
Total cholesterol (mg/dL) 203.1±35.1 203.9±34.20 201.9±36.5
LDL-C (mg/dL) 111.2±28.2 112.6±27.5* 109.0±29.0
HDL-C (mg/dL) 055.3±13.3 051.9±11.9* 060.6±13.5
Triglyceride (mg/dL) 129.7±81.0 149.8±88.3* 098.9±55.8
Fasting blood glucose (mg/dL) 093.2±21.2 095.8±23.3* 089.3±16.6
Glycated hemoglobin (%) 05.7±0.7 05.8±0.8* 05.6±0.6
BUN (mg/dL) 12.9±3.5 13.5±3.6* 12.0±3.2
Serum creatinine (mg/dL) 01.1±0.2 01.1±0.2* 00.9±0.1
CRP (mg/dL) 00.13±0.54 00.15±0.56* 00.09±0.49
Data are expressed as number (%) or means±standard deviation. *p<0.05 compared with female group. BMI: body mass index, CAD: 
coronary artery disease, FRS: framingham risk score, NCEP-ATP: National Cholesterol Education Program-Adult Treatment Program, CACS: 
coronary artery calcium score, LDL-C: low density lipoprotein-cholesterol, HDL-C: high density lipoprotein-cholesterol, BUN: blood urea 
nitrogen, CRP: C-reactive protein
Sahmin Lee, et al.   437
Prevalence of subclinical coronary artery disease
An abnormal finding on CCTA, defined as the presence of 
any plaque or a CACS greater than 0, was seen in 24% (n= 
1,053) of the total population. Subjects with significant steno-
sis (n=139) made up 3% of the total study population and 13% 
of the group with abnormal findings. Most of those with sig-
nificant stenosis (n=121) had lesions which were located in the 
left anterior descending coronary artery (LAD), and 10% (n= 
14) had significant stenotic lesions in the left main coronary 
artery. While 98 subjects with significant stenosis (71%) had 
single-vessel disease, multi-vessel disease was found in 29% 
(n=41) of those with significant stenosis, or about 1% of the 
total population (Table 2).
Plaque characteristics 
There were 975 subjects randomly selected for plaque ana-
lysis (Fig. 2). Clinical characteristics of the selected population 
are described in supplemental Table 1. They were similar to 
the characteristics of the total study population; the popula-
tion generally was at low or intermediate risk and men were 
more predisposed to CHD risk than women. Most subjects 
(n=801, 82%) had coronary calcium scores of 0, whereas 1% 
(n=10) of the total selected population had severe calcifica-
tion (CACS >400). Similarly, there were no plaques seen in 
most subjects (n=761, 78%), whereas 40 individuals (4%) 
had noncalcified plaques only (Table 3). Although 25% (n= 
10) of those with noncalcified plaques had significant steno-
Table 2. Subclinical coronary artery disease on CCTA
Total (n=4,320) Male (n=2,615) Female (n=1,705)
Abnormal CCTA findings† 1,053 (24)000 826 (32)*. 227 (13)00
Significant luminal narrowings‡ 139 (3)00. 121 (5)*0 18 (1)00
Location of significant lesions
Left main 14 (0.3) 010 (0.4)* 4 (0.2)
LAD 121 (2.8)0 106 (4.1)* 15 (0.9)0
LCX 29 (0.7) 26 (1.0) 3 (0.2)
RCA 28 (0.6) 27 (1.0) 01 (0.06).
Number of stenotic vessels§
1-vessel 98 (2.3) 084 (3.2)* 14 (0.8)0
2-vessel 30 (0.7) 028 (1.1)* 2 (0.1)
3-vessel 11 (0.3) 0 9 (0.3)* 2 (0.1)
Data are expressed as number (%). *p<0.05 compared with female group, †Any plaque or any abnormal coronary calcium score, ‡Luminal 
diameter stenosis greater than 50%, §Diseased vessel having significant luminal diameter stenosis. CCTA: coronary computed tomography 
angiography, LAD: left anterior descending artery, LCX: left circumflex artery, RCA: right coronary artery
Plaque characteristics analysis
Coronay CT angiography
with calcium scoring (n=975)
Coronary artery
calcium score=0 
(n=174)
Coronary artery
calcium score=0 
(n=801)
No plaques (n=761) Non-calcified plaque only (n=40)
Non-calcified 
or mixed plaque (n=84) Calcified plaque (n=90)
No CAD Subclinical CAD
Fig. 2. Study population according to analysis of plaque characteristics. CAD: coronary artery disease.
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sis, 40% (n=4) of them were classified into the low-risk group 
according to conventional risk stratification methods (the re-
vised NCEP guidelines). 
 
Significant subclinical coronary artery disease-
prevalence and the relationship to National 
Cholesterol Education Program risk stratification 
and coronary artery calcium score according to age
As described above, the prevalence of significant subclini-
cal CAD in this asymptomatic study population was 3% (n= 
139). When the total study population was divided according 
to age, the prevalence of significant subclinical CAD in the 
older age group (age >55 years for male, age >65 years for fe-
male) was higher than that in the younger age group (10% vs. 
2%, respectively; p<0.001). 
When subjects were divided according to NCEP risk strat-
ification, the prevalences of significant subclinical CAD in 
each risk group were as follows: 1%, 5%, and 9% in low-, mo-
derate-, and high-risk groups respectively. Especially in the 
low-risk population, the higher prevalences of significant sub-
clinical CAD were seen in male subjects or subjects in the old-
er age group {1% in total low-risk population, 3% in male, 7% 
in older age group (Table 4)}.
Similarly, when subjects were divided according to CACS, 
the prevalence of significant subclinical CAD in each catego-
rized group (no, 0; mild, 0.1 to 100; moderate, 100.1 to 400; 
and severe calcification, >400) were as follows: 0.7%, 8%, 29%, 
and 45% in no, mild, moderate and severe calcification groups, 
respectively. Also, among those with a calcium score of 0, which 
means no calcification, the prevalence of significant subclin-
ical CAD was about 2-fold (1.2%) greater in males and about 
3-fold (2.2%) higher in the older age group than the preva-
lence among all subjects with coronary calcium scores of 0 
(Table 4).
Moreover, when the group with significant stenosis (n= 
139) was divided according to NCEP risk stratifications, 26% 
(n=36) of those with significant stenosis were classified into 
the low-risk group, which was more pronounced in the yo-
unger age group than in older group (30% vs. 22%, respec-
tively; p=0.356) (Fig. 3A). Also, when subjects with significant 
stenosis were categorized according to CACS, almost half 
(50%) (n=69) of them had mild calcification (CACS 0.1 to 
100) or no calcification (CACS 0). In those with significant 
stenosis, the younger age group was shown to have less calci-
fication (≤100 CACS) than the older age group (60% vs. 39%, 
respectively; p=0.046). Otherwise, 28 (20%) subjects with 
significant stenosis had severe calcification (CACS >400), 
with higher prevalence in the older age group than in the 
younger group (28% vs. 13%, respectively; p=0.046) (Fig. 3B).
Discussion
The clinical characteristics of the asymptomatic study pop-
ulation according to gender are listed in Table 1. This table sh-
ows that men are more likely to have CHD risk factors, which 
makes them particularly susceptible to acute coronary syn-
dromes. The study population generally was at low or inter-
Table 3. Plaque characteristics on CCTA
Total
(n=975)
Male
(n=622)
Female
(n=353)
CACS
0 801 (82) 477 (77)* 324 (92)
0.1-100 127 (13) 104 (17)* 23 (7)
100.1-400 37 (4) 31 (5)* 06 (2)
>400 10 (1) 10 (2)* 00 (0)
Plaque (per-subject)
No plaques 761 (78) 444 (71)* 317 (90)
Non-calcified plaque only 40 (4) 33 (5)* 07 (2)
Non-calcified 
  or mixed plaque
84 (9) 068 (11)* 16 (5)
Calcified plaque 90 (9) 077 (12)* 13 (4)
Data are expressed as number (%). *p<0.05 compared with female 
group. CACS: coronary artery calcium score
Table 4. Prevalence of significant subclinical atherosclerosis according to NCEP-ATP III risk stratification or coronary artery calcium score
Total (n=4,320) Male (n=2,615) Female (n=1,705) Young age (n=3,641) Old age (n=679)
NCEP
Low risk 36/2,645 (1)0. 32/1,261 (3)0. 4/1,384 (0.3) 21/2,422 (0.9) 15/223 (7)0
Moderate risk 69/1,260 (5)0. 59/1,053 (6)0. 10/237 (4)0 35/959 (4) 34/331 (10)
High risk 34/385 (9) . 30/301 (10) 04/84 (5) 14/260 (5) 20/125 (16)
CACS
0 25/3,558 (0.7) 24/2,022 (1.2) 1/1,536 (0.1) 17/3,209 (0.5) 0.8/349 (2.2)
0.1-100 44/554 (8) 39/425 (9) 5/129 (4) 25/352 (7) 19/202 (9)0
100.1-400 042/146 (29) 032/114 (28) 010/32 (31) 0019/59 (32) 023/87 (26)
>400 0028/62 (45) 0026/54 (48) 0002/8 (25) 0009/21 (43) 019/41 (46)
Data are expressed as number of subjects with significant subclinical atherosclerosis/number of total subjects in each subgroup (%). NCEP-ATP: 
National Cholesterol Education Program-Adult Treatment Panel, CACS: coronary artery calcium score
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mediate risk, and low and intermediate risk was more freque-
nt in females. Findings from this study should be cautiously 
applied, because all subjects in the study were self-referred and 
were drawn from the same ethnic background and geograph-
ical region. Additionally, in such a low-risk population, the prog-
nostic accuracy of CAD screening is far from perfect, as pre-
viously reported.5)6) Hence, the incorporation of CCTA imag-
ing data into a conventional CAD risk scoring system may im-
prove the existing algorithms for risk stratification.
The present study revealed that the prevalence of subclini-
cal CAD in asymptomatic individuals was not negligible. A 
significant percentage of the population (24%) had evidence 
of subclinical CAD despite the absence of symptoms, and of 
those, 3% (n=139) had at least one significant stenotic coro-
nary artery. Moreover, most significant subclinical stenosis 
was found in the left main or proximal LAD. The presence of 
left main or proximal LAD atherosclerotic disease as docu-
mented by multi-slice CCTA, has been known to be associ-
ated with a worse prognosis.20) 
A number of individuals with subclinical CAD or even wi-
th significant stenosis were frequently misclassified into the 
low-risk group by conventional risk stratification algorithms. 
The CACS, however, provides prognostic information over 
traditional risk factors, and recently was proposed as an index 
parameter of routine screening, especially among those with 
low or intermediate risk.11)12) Patients with high coronary cal-
cium were at higher risk for obstructive and nonobstructive 
CAD than patients with low or zero coronary calcium, and 
probably for coronary events as well. Asymptomatic individ-
uals with low calcium scores were less likely to have obstruc-
tive atherosclerosis, and the negative predictive value for pre-
dicting near-future coronary events was high (92-98%).21)22)
Then what is the additional diagnostic value of CCTA im 
aging compared with EBCT coronary calcium scanning? Al-
though CACS does reflect plaque burden and consequently 
remains an unequivocal biomarker for the presence and ex-
tent of atherosclerotic disease,10)11) EBCT alone cannot detect 
A  B  
Fig. 3. Conventional risk stratification according to (A) NCEP risk stratification and (B) coronary artery calcium scores (CACSs), in an asymp-
tomatic, significantly atheroscleroticsis population identified by using CCTA. NCEP: National Cholesterol Education Program, CCTA: coro-
nary computed tomography angiography.
M ≤55, F ≤65 M ≤55, F ≤65M >55, F >65 M >55, F >65
80 60
60 45
40 30
20 15
0 0
Low-risk
Moderate-risk
High-risk
0
0.1-100
100.1-400
>400.1
noncalcified or mixed plaques. However, CCTA can not only 
document the presence of coronary atherosclerosis, but also 
can provide comprehensive information on CAD, including 
location, severity, and plaque characteristics, as demonstrat-
ed in a previous study.18) In the of those present study, asymp-
tomatic subjects usually had negative findings by coronary 
calcium scanning, but 5% found by CCTA were seen to have 
noncalcified plaques, and the presence of noncalcified plaques 
was the only manifestation of subclinical CAD. Our result is 
consistent with other previous studies showing a considerable 
prevalence of noncalcified plaques.23)24) Despite the high known 
negative predictive value of CACS for coronary events, a low 
or even zero calcium score does not rule out significant sub-
clinical atherosclerosis. Particularly in young adults, signifi-
cant atherosclerosis can be present without any detectable cal-
cium, which implies that there is a possibility that conventional 
CACS used as a screening tool could underestimate subclin-
ical CAD, especially in the young age group. Therefore, com-
prehensive coronary imaging using CCTA to assess total cor-
onary plaque burden and characteristics may be superior to 
simple calcium scoring.
Multidetector CCTA has been reported to have sufficient 
diagnostic accuracy for significant coronary artery stenosis, 
with 90% sensitivity, 94% specificity, and 95% negative pre-
dictive value.25) However, the positive and negative predictive 
values of CCTA are dependent on the pretest probability of 
disease, so that the diagnostic accuracy of CCTA substantial-
ly declines in the asymptomatic low risk population. Apart 
from diagnostic utility, CCTA still has some important limi-
tations as a screening tool. First, CCTA cannot provide func-
tional information, and there have been few studies to dem-
onstrate that CCTA-guided early treatment improves outcom-
es. Also, cost-effectiveness and radiation hazards should be ta-
ken into consideration when performing CT screening.
In conclusion, noninvasive CCTA imaging detected con-
siderable subclinical CAD, even in the young or traditionally 
low-risk population. Although there have been few studies 
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showing that CCTA imaging in asymptomatic subjects will 
result in better risk stratification and improvement of out-
comes compared with calcium scoring alone CCTA imaging 
of coronary plaques may provide better insight into subclini-
cal CAD. However, additional studies should be carried out 
before integrating CCTA into the overall assessment of car-
diac risk and employing it as a cost-effective method for guid-
ing the provision of expensive and prolonged preventive 
therapy.
To identify asymptomatic patients at risk for acute ische-
mic events more accurately, we should reinforce the existing 
guidelines for screening, especially in the young and tradi-
tionally low-risk population, and also avoid recommending 
unproven therapies or expensive tests based on CT technol-
ogy that is still evolving.
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Supplemental Table 1. Clinical characteristics of population randomly selected for plaque analysis
Total (n=975) Male (n=622) Female (n=353)
Age (yrs) 50±9 48±8* 51±9
BMI (kg/m2) 24.2±2.7 24.8±2.5* 23.0±2.6
Obesity (BMI >25) 363 (37) 288 (46)* 075 (21)
Hypertension 182 (19) 131 (21)* 051 (14)
Diabetes 096 (10) 077 (12)* 19 (5)
Dyslipidemia 145 (15) 108 (17)* 037 (10)
Smoking 328 (34) 312 (50)* 16 (5)
Family Hx of premature CAD 125 (13) 83 (13) 042 (12)
FRS (10 year-risk) 05.3±5.0 07.4±5.2* 01.6±1.4
NCEP-ATP III risk stratification
High-risk group 109 (11) 085 (14)* 24 (7)
Moderate-risk group 287 (29) 246 (40)* 041 (12)
Low-risk group 579 (59) 291 (47)* 288 (82)
CACS 018.0±83.4 0025.5±102.0* 004.8±24.9
Systolic blood pressure (mmHg) 115.9±14.2 117.6±13.7* 112.8±14.6
Diastolic blood pressure (mmHg) 074.4±11.7 077.7±10.3* 068.5±11.5
Total cholesterol (mg/dL) 204.8±34.3 205.8±32.9. 203.0±36.7
LDL cholesterol (mg/dL) 117.9±32.2 117.9±31.5. 117.8±33.4
HDL cholesterol (mg/dL) 060.0±14.0 056.7±12.8* 065.9±14.4
Triglyceride (mg/dL) 134.3±90.6 155.9±99.6* 096.2±54.0
Fasting blood glucose (mg/dL) 097.6±24.7 100.7±27.9* 092.0±16.4
Glycated hemoglobin (%) 05.8±0.8 05.8±0.8* 05.7±0.6
BUN (mg/dL) 13.1±3.4 13.6±3.5* 12.1±3.1
Serum creatinine (mg/dL) 01.1±0.2 01.2±0.1* 00.9±0.1
CRP (mg/dL) 00.13±0.33 00.15±0.39* 00.09±0.22
Data are expressed as number (%) or means ± standard deviation. *p<0.05 compared with female group. BMI: body mass index, CAD: coro-
nary artery disease, FRS: Framingham risk score, NCEP-ATP: National Cholesterol Education Program-Adult Treatment Panel, CACS: coro-
nary artery calcium score, LDL: low density lipoprotein, HDL: high density lipoprotein, BUN: blood urea nitrogen, CRP: C-reactive protein
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